Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adebrelimab - Atridia

Next Previous
Drug Profile

Adebrelimab - Atridia

Alternative Names: HTI-1088; HTI-1316; SHR 1316

Latest Information Update: 17 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Atridia; Jiangsu Hengrui Medicine Co.; Shandong Cancer Hospital and Institute
  • Developer Atridia; Jiangsu Hengrui Medicine Co.; Shandong Cancer Hospital and Institute; Sheng Jing Hospital; Suzhou Suncadia Biopharmaceuticals
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Small cell lung cancer
  • Phase III Cervical cancer; Non-small cell lung cancer; Urogenital cancer
  • Phase II Adenocarcinoma; Oesophageal cancer
  • No development reported Breast cancer; Cancer; Haematological malignancies; Solid tumours

Most Recent Events

  • 13 Apr 2026 Shanghai Shengdi Pharmaceutical plans a phase III trial for Gastric cancer and Oesophageal cancer (neoadjuvant therapy) in China in May 2026 (NCT07522151)
  • 10 Mar 2026 Phase-III clinical trials in Urogenital cancer (First-line therapy, Metastatic disease, Inoperable/Unresectable, Late-stage disease, Combination therapy) in China (IV) (NCT07393542)
  • 01 Mar 2026 Suzhou Suncadia Biopharmaceuticals plans a phase II/III trial for Rectal cancer (Combination therapy, First-line therapy, Late-stage disease, Neoadjuvant therapy) in China (NCT07454720)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top